Hemocompatibility of magnetic magnethite nanoparticles and magnetite-silica composites in vitro

Y. G. Toropova, N. A. Pechnikova, I. A. Zelinskaya, D. V. Korolev, K. G. Gareev, A. S. Markitantova, V. D. Bogushevskaya, A. V. Povolotskaya, A. A. Manshina

Research output

3 Citations (Scopus)

Abstract

The goal of the present research is to study the hemocompatibility of magnetic nanoparticles (MNPs) in model systems in vitro. Materials and methods. Magnetite nanoparticles and magnetite colloidal solutions were used in 0.9% NaCl in concentrations 0.2, 2.0 and 20.0 mg/ml. The study was performed with heparinized human whole blood, 1 ml of which was mixed with 1 of ml nanoparticles/physiological solution. Measurements were made directly after mixing, and then 1, 2.5 and 5 hours later. The amount of reactive oxygen species (ROS) was measured with luminol-dependent chemiluminiscence (CL). An erythrocyte aggregation index was calculated. For the assessment of hemolytic properties, a hemolysis coefficient was calculated based on optical density of the plasma. The nanoparticless surface protein layer investigation was performed with IR-Fourier spectroscopy. Results. Nanoparticles decline CL in time- and concentration-dependent manner. Erythrocyte aggregation stability grows, but concentration and/or application time increment leads to significant hemolysis. IR-Fourier spectroscopy data shows albumin as main component of protein crown, whose conformationc hanges in time. Given data proves safety of studied MNPs in relation to examined parameters in low (0.2 and 2.0 mg/ml) concentrations up to 2.5 hours interaction. This allows us to treat these MNPs as a promising agents for further use in medical practice after completing examinations related to other homeostasis indicators.

Original languageEnglish
Pages (from-to)157-167
Number of pages11
JournalBulletin of Siberian Medicine
Volume17
Issue number3
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Magnetite Nanoparticles
Silicon Dioxide
Nanoparticles
Erythrocyte Aggregation
Hemolysis
Spectrum Analysis
Ferrosoferric Oxide
Luminol
Erythrocyte Indices
Crowns
Albumins
Reactive Oxygen Species
Homeostasis
In Vitro Techniques
Safety
Research
Proteins

Scopus subject areas

  • Molecular Medicine

Cite this

Toropova, Y. G. ; Pechnikova, N. A. ; Zelinskaya, I. A. ; Korolev, D. V. ; Gareev, K. G. ; Markitantova, A. S. ; Bogushevskaya, V. D. ; Povolotskaya, A. V. ; Manshina, A. A. / Hemocompatibility of magnetic magnethite nanoparticles and magnetite-silica composites in vitro. In: Bulletin of Siberian Medicine. 2018 ; Vol. 17, No. 3. pp. 157-167.
@article{8304150dcb064f18acfb95f3a9cb3686,
title = "Hemocompatibility of magnetic magnethite nanoparticles and magnetite-silica composites in vitro",
abstract = "The goal of the present research is to study the hemocompatibility of magnetic nanoparticles (MNPs) in model systems in vitro. Materials and methods. Magnetite nanoparticles and magnetite colloidal solutions were used in 0.9{\%} NaCl in concentrations 0.2, 2.0 and 20.0 mg/ml. The study was performed with heparinized human whole blood, 1 ml of which was mixed with 1 of ml nanoparticles/physiological solution. Measurements were made directly after mixing, and then 1, 2.5 and 5 hours later. The amount of reactive oxygen species (ROS) was measured with luminol-dependent chemiluminiscence (CL). An erythrocyte aggregation index was calculated. For the assessment of hemolytic properties, a hemolysis coefficient was calculated based on optical density of the plasma. The nanoparticless surface protein layer investigation was performed with IR-Fourier spectroscopy. Results. Nanoparticles decline CL in time- and concentration-dependent manner. Erythrocyte aggregation stability grows, but concentration and/or application time increment leads to significant hemolysis. IR-Fourier spectroscopy data shows albumin as main component of protein crown, whose conformationc hanges in time. Given data proves safety of studied MNPs in relation to examined parameters in low (0.2 and 2.0 mg/ml) concentrations up to 2.5 hours interaction. This allows us to treat these MNPs as a promising agents for further use in medical practice after completing examinations related to other homeostasis indicators.",
keywords = "Chemiluminescence, Erythrocyte aggregation, Hemocompatibility, Hemolysis, IR-Fourier spectroscopy, Magnetic nanoparticles, «albuminous crown»",
author = "Toropova, {Y. G.} and Pechnikova, {N. A.} and Zelinskaya, {I. A.} and Korolev, {D. V.} and Gareev, {K. G.} and Markitantova, {A. S.} and Bogushevskaya, {V. D.} and Povolotskaya, {A. V.} and Manshina, {A. A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.20538/1682-0363-2018-3-157-167",
language = "English",
volume = "17",
pages = "157--167",
journal = "БЮЛЛЕТЕНЬ СИБИРСКОЙ МЕДИЦИНЫ",
issn = "1682-0363",
publisher = "Siberian State Medical University",
number = "3",

}

Toropova, YG, Pechnikova, NA, Zelinskaya, IA, Korolev, DV, Gareev, KG, Markitantova, AS, Bogushevskaya, VD, Povolotskaya, AV & Manshina, AA 2018, 'Hemocompatibility of magnetic magnethite nanoparticles and magnetite-silica composites in vitro', Bulletin of Siberian Medicine, vol. 17, no. 3, pp. 157-167. https://doi.org/10.20538/1682-0363-2018-3-157-167

Hemocompatibility of magnetic magnethite nanoparticles and magnetite-silica composites in vitro. / Toropova, Y. G.; Pechnikova, N. A.; Zelinskaya, I. A.; Korolev, D. V.; Gareev, K. G.; Markitantova, A. S.; Bogushevskaya, V. D.; Povolotskaya, A. V.; Manshina, A. A.

In: Bulletin of Siberian Medicine, Vol. 17, No. 3, 01.01.2018, p. 157-167.

Research output

TY - JOUR

T1 - Hemocompatibility of magnetic magnethite nanoparticles and magnetite-silica composites in vitro

AU - Toropova, Y. G.

AU - Pechnikova, N. A.

AU - Zelinskaya, I. A.

AU - Korolev, D. V.

AU - Gareev, K. G.

AU - Markitantova, A. S.

AU - Bogushevskaya, V. D.

AU - Povolotskaya, A. V.

AU - Manshina, A. A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The goal of the present research is to study the hemocompatibility of magnetic nanoparticles (MNPs) in model systems in vitro. Materials and methods. Magnetite nanoparticles and magnetite colloidal solutions were used in 0.9% NaCl in concentrations 0.2, 2.0 and 20.0 mg/ml. The study was performed with heparinized human whole blood, 1 ml of which was mixed with 1 of ml nanoparticles/physiological solution. Measurements were made directly after mixing, and then 1, 2.5 and 5 hours later. The amount of reactive oxygen species (ROS) was measured with luminol-dependent chemiluminiscence (CL). An erythrocyte aggregation index was calculated. For the assessment of hemolytic properties, a hemolysis coefficient was calculated based on optical density of the plasma. The nanoparticless surface protein layer investigation was performed with IR-Fourier spectroscopy. Results. Nanoparticles decline CL in time- and concentration-dependent manner. Erythrocyte aggregation stability grows, but concentration and/or application time increment leads to significant hemolysis. IR-Fourier spectroscopy data shows albumin as main component of protein crown, whose conformationc hanges in time. Given data proves safety of studied MNPs in relation to examined parameters in low (0.2 and 2.0 mg/ml) concentrations up to 2.5 hours interaction. This allows us to treat these MNPs as a promising agents for further use in medical practice after completing examinations related to other homeostasis indicators.

AB - The goal of the present research is to study the hemocompatibility of magnetic nanoparticles (MNPs) in model systems in vitro. Materials and methods. Magnetite nanoparticles and magnetite colloidal solutions were used in 0.9% NaCl in concentrations 0.2, 2.0 and 20.0 mg/ml. The study was performed with heparinized human whole blood, 1 ml of which was mixed with 1 of ml nanoparticles/physiological solution. Measurements were made directly after mixing, and then 1, 2.5 and 5 hours later. The amount of reactive oxygen species (ROS) was measured with luminol-dependent chemiluminiscence (CL). An erythrocyte aggregation index was calculated. For the assessment of hemolytic properties, a hemolysis coefficient was calculated based on optical density of the plasma. The nanoparticless surface protein layer investigation was performed with IR-Fourier spectroscopy. Results. Nanoparticles decline CL in time- and concentration-dependent manner. Erythrocyte aggregation stability grows, but concentration and/or application time increment leads to significant hemolysis. IR-Fourier spectroscopy data shows albumin as main component of protein crown, whose conformationc hanges in time. Given data proves safety of studied MNPs in relation to examined parameters in low (0.2 and 2.0 mg/ml) concentrations up to 2.5 hours interaction. This allows us to treat these MNPs as a promising agents for further use in medical practice after completing examinations related to other homeostasis indicators.

KW - Chemiluminescence

KW - Erythrocyte aggregation

KW - Hemocompatibility

KW - Hemolysis

KW - IR-Fourier spectroscopy

KW - Magnetic nanoparticles

KW - «albuminous crown»

UR - http://www.scopus.com/inward/record.url?scp=85054567765&partnerID=8YFLogxK

U2 - 10.20538/1682-0363-2018-3-157-167

DO - 10.20538/1682-0363-2018-3-157-167

M3 - Article

AN - SCOPUS:85054567765

VL - 17

SP - 157

EP - 167

JO - БЮЛЛЕТЕНЬ СИБИРСКОЙ МЕДИЦИНЫ

JF - БЮЛЛЕТЕНЬ СИБИРСКОЙ МЕДИЦИНЫ

SN - 1682-0363

IS - 3

ER -